Eurobio Scientific — Cyborg Score 7/10

Strong
In Vitro Diagnostics (IVD) / Life Sciences

Strategic Profile

The company has extensive distribution networks and a portfolio of proprietary products in molecular biology. Eurobio Scientific is executing strategic priorities including development of proprietary products, internationalization, and opening new markets to enable sustained sales and margin growth. As of December 2024, EB Development held 89.11% of share capital through strategic alignment with NextStage AM and IK Partners.

Cyborg Score Rationale

The company demonstrated strong 19% reported growth and 9% organic growth in 2024, reflecting solid market execution. However, the group faces increasing margin pressure and difficulties in some European subsidiaries, which tempers growth momentum. Strong proprietary product positioning and international expansion provide long-term upside.

Top Insights

  • 19% reported revenue growth with 9% organic growth demonstrates core business strength beyond acquisitions
  • Strategic 2024 acquisition of EndoPredict and Prolaris licenses from Myriad Genetics expands oncology/cancer diagnostics portfolio
  • EB Development's majority stake consolidation (89.11%) with NextStage AM and IK Partners provides growth capital and institutional expertise
  • Global footprint spans 8 countries with ~320 employees and production units across Paris region, Germany, Netherlands, and US

Named Competitors

  • Transplantation & Immunology Diagnostics — Established competitors in blood bank and immunodiagnostics
  • Oncology Genomics Testing — EndoPredict and Prolaris tests (now distributed by Eurobio)
  • Infectious Disease & Research Diagnostics — Fragmented market with regional distribution focus

Recent Developments

  • (May 2024) EB Development surpassed 90% shareholding threshold through market acquisitions
  • (August 2024) Acquired EndoPredict and Prolaris diagnostic tests from Myriad Genetics for breast and prostate cancer
  • (April 2025) Reported 2024 results with €154.2M revenue (+19%) and strategic focus on proprietary product development

Open the full interactive Eurobio Scientific report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →